Verition Fund Management
BBNX

Verition Fund Management’s Beta Bionics BBNX Stock Holding History

Verition Fund Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$255K Sell
25,427
-57,435
-69% -$850K ﹤0.01% 1854
2025
Q4 		$2.52M Buy
82,862
+35,563
+75% +$950K 0.01% 1401
2025
Q3 		$940K Buy
47,299
+1,823
+4% +$32K ﹤0.01% 2580
2025
Q2 		$662K Buy
45,476
+18,259
+67% +$258K ﹤0.01% 2764
2025
Q1 		$333K Buy
+27,217
New +$507K ﹤0.01% 2815

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Verition Fund Management's BBNX Position: Q1 2026 in Review

Verition Fund Management reduced its Beta Bionics (BBNX) stake by 69% in Q1 2026, selling an estimated $850K and leaving 25,427 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #1854.

Verition Fund Management first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.52M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Verition Fund Management held 25,427 shares of Beta Bionics worth $255K as of Q1 2026.
  • Verition Fund Management sold 57,435 Beta Bionics shares in Q1 2026, an estimated $850K.
  • Beta Bionics made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #1854 holding.
  • Verition Fund Management first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • Verition Fund Management's Beta Bionics position peaked at $2.52M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.